DLB Diagnosis Challenges

75% of DLB patients are initially given a wrong diagnosis.

A man performing Alzheimer's disease research

SYNTap Test Capabilities

This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.

Specification Sheet

SYNTap Spec Sheet - Disease Lead

“According to the Lewy Body Dementia Association (LBDA), its takes an average of three doctors and more than 18 months to correctly diagnose DLB. Most doctors fail to recognize the signs of DLB; the symptoms are very similar to Alzheimer’s disease and other neurodegenerative disorders, such as Parkinson’s disease” (Ref.3)

Accurate Early Diagnosis Aids Proper Disease Management

Identifying DLB earlier in the disease can aid in making therapeutic decisions

SYNTap Biomarker Test provides clinicians with valuable information to make an early diagnosis, helping to avoid medications, which can bring on severe side effects in DLB patients.

“Many commonly used medications can produce severe side effects in patients with DLB, notably medications with anticholinergic or antidopaminergic actions. Substantial improvement in quality of life can be achieved by ceasing these treatments.”  (Ref.7)

“Common difficulties in establishing diagnosis included atypical or non-specific presentations, conditions with very low prevalence, the presence of co-morbid illnesses and perceptual features, which are all characteristic of LBD.”  (Ref.3)

Download the SYNTap Test Specification Sheet for details.

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.